Menu Search
Equities

Shanghai Henlius Biotech Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2696:HKG.HZ

Shanghai Henlius Biotech Inc

Actions
  • Price (HKD)68.90
  • Today's Change-1.45 / -2.06%
  • Shares traded81.10k
  • 1 Year change+227.32%
  • Beta0.9021
Data delayed at least 15 minutes, as of Feb 16 2026 02:37 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Shanghai Henlius Biotech Inc is a China-based company principally engaged in biopharmaceutical research and development, biopharmaceutical services and biopharmaceutical production and sales. The Company’s main products include HANQUYOU (trastuzumab for injection), HANNAIJIA (neratinib maleate), HANSIZHUANG (serplulimab injection), HANLIKANG (rituximab injection), HANDAYUAN (adalimumab injection), HANBEITAI (bevacizumab injection) and others. The Company’s products are mainly used in the treatment of adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, metastatic non-squamous non-small cell lung cancer, polyarticular juvenile idiopathic arthritis and others. The Company mainly operates its businesses in the domestic and overseas markets.

  • Revenue in HKD (TTM)6.56bn
  • Net income in HKD932.54m
  • Incorporated2010
  • Employees3.54k
  • Location
    Shanghai Henlius Biotech Inc11/F, B8 Building, No. 188 Yizhou Road,SHANGHAI 200233ChinaCHN
  • Fax+86 2 134611802
  • Websitehttps://www.henlius.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.